Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating epstein-barr virus - positive cancer with immunotherapy

a technology of epstein-barr virus and immunotherapy, which is applied in the field of immunotherapy for epstein-barr virus-positive cancer, can solve the problems of limited treatment options for metastatic disease, limited use of npc, and inability to identify reliable biomarkers to predict the efficacy of checkpoint inhibitors, etc., and achieve the effect of accurately identifying one- and two-year survivors

Inactive Publication Date: 2019-12-19
TESSA THERAPEUTICS PTE LTD +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method for treating a disease by using adoptive cell transfer (ACT). This method involves administering certain substances that decrease the number or activity of immune cells that can suppress the immune response, decrease the number of regulatory T cells that can inhibit immune responses, increase the number of effector T cells that can enhance immune responses, or reduce the amount of infectious agents associated with the disease. The invention also provides specific proteins that can be measured in patients to identify those who will benefit from ACT therapy for the treatment of EBV-positive NPC. This information can help to correctly power downstream analysis and improve the effectiveness of this therapy.

Problems solved by technology

Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) represents a significant health-care problem for South-East Asia.
Current therapies are effective in controlling and curing non-metastasized NPC, however treatments for metastatic disease are limited.
Whilst there has been great progress in the application of checkpoint inhibitor blockade against tumors, their use against NPC has been limited.
Furthermore, to date there has been no identification of a reliable biomarker to predict checkpoint inhibitor efficacy.
CAR-T therapy has shown much promise against melanomas and lymphomas but has shown limited efficacy in clearing solid tumors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating epstein-barr virus - positive cancer with immunotherapy
  • Method for treating epstein-barr virus - positive cancer with immunotherapy
  • Method for treating epstein-barr virus - positive cancer with immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

tal Procedures

[0365]1.1 Immunotherapy Trial and Sample Collection

[0366]A Phase II clinical trial was performed in which Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) patients were treated with gemcitabine and carboplatin for four cycles, followed by treatment by adoptive transfer of autologous, in vitro expanded, EBV-specific CD8+ T-cells.

[0367]The results demonstrated unprecedented efficacy. The two-year overall survival rate was 62.9%, and the three-year overall survival rate was 37.1%. These two- and three-year overall survival rates are amongst the best survival rates for treatment of advanced NPC.

[0368]Analysis of the Phase II trial data showed that there was a positive correlation between long-term survivors and the ability of their CTLs to produce IFN-γ in response to LMP2 antigen presentation.

[0369]Throughout the immunotherapy trial peripheral blood was sampled from the patients. The time points examined were:[0370]Pre chemotherapy (T−1);[0371]Post chemoth...

example 2

Survivors Experience Increased Lymphoid but Decreased Myeloid Numbers Post CTL Immunotherapy

[0392]Throughout the immunotherapy trial peripheral blood was sampled from the patients. In order to assess the impact of immunotherapy analysis was focused on the time point two weeks after the first immunotherapy infusion (T1; see FIG. 1).

[0393]The numbers of peripheral blood leukocytes at time point T1 were assessed to detect any gross changes in the immune system as a result of immunotherapy. The results are shown in FIGS. 2A to 2E.

[0394]There was a significant negative correlation between the number of leukocytes and overall survival (r=−0.43; FIG. 2A). Neutrophil numbers (as a proportion of leukocytes) were also significantly, negatively associated with survival, albeit with poor correlation (r=−0.32; FIG. 2B). Conversely there was a significant positive correlation between lymphocyte numbers (as a proportion of leukocytes) and overall survival (r=0.46; FIG. 2C). No correlation was obse...

example 3

l CTL Immunotherapy Results in Increased IFNγ

[0396]In order to assess whether or not the increase in lymphocyte numbers was also influencing viral load and cytokine production, patient sera was analysed for cytokine production by luminex assay, and EBV DNA was quantified by qPCR. The results of the analyses are shown in FIG. 4A to 4F. The data shown in FIGS. 4A to 4D, 5, 6 and 7A and 7B is based on analysis of serum obtained from samples isolated at time point T1, i.e. two weeks after the first infusion of EBV-specific CTL.

[0397]Within two weeks after the first immunotherapy infusion there was a significant positive correlation between IFNγ production and survival (FIG. 4A). Prior to immunotherapy (i.e. at T0), there was no correlation was observed between survival and IFNγ concentrations in the sera (Table 2, FIG. 5). Conversely, survival was strongly correlated with a significant decrease in EBV viral load (FIG. 4B). Production of myeloid-expressed chemokines such as CCL20 was sim...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analysing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT. Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 15 / 594,167 entitled “METHOD FOR TREATING EPSTEIN-BARR VIRUS—POSITIVE CANCER WITH IMMUNOTHERAPY” filed May 12, 2017, which claims priority to and is a continuation of application PCT / SG2016 / 050441, filed Sep. 9, 2016, which claims priority to Singapore Application No. 10201509979S, filed Dec. 4, 2015, all of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to treatment of disease by adoptive cell transfer (ACT), and in particular to the prediction of long-term survival on treatment of a disease by ACT based on analysis of correlates of long-term survival in blood or blood-derived samples obtained from patients.BACKGROUND OF THE INVENTION[0003]The following description provides a summary of information relevant to the present disclosure and is not an admission that any of the information provided or publications referenced here...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/245G01N33/574C12Q1/70C12N7/00C12Q1/6886C12Q1/68A61K35/17
CPCC12Q2600/158G01N2800/52A61K39/245C12Q1/705C12Q1/68A61K2039/545G01N33/57438G01N2333/57C12Q2600/106C12Q1/701G01N33/574A61K2039/585G01N33/57446C12Q2600/118C12N2710/16271G01N33/57407G01N33/57423G01N2333/521A61K2039/5158C12Q1/6886C12N2710/16234G01N2333/05C12N7/00A61K35/17A61K2039/572A61K2039/57A61P11/02A61P11/04A61P31/12A61P31/22A61P35/00A61P37/04A61P43/00A61K39/464838A61K39/4611G01N33/57488G01N33/57496G01N33/6863
Inventor CONNOLLY, JOHNHOPKINS, RICHARDTOH, HAN CHONG
Owner TESSA THERAPEUTICS PTE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com